Ibrance (Palbociclib)

At a Glance
Therapeutic Area:
HR+, HER2- adjuvant breast cancer
Approved Applications:
IBRANCE® (palbociclib) is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, fulvestrant in women with disease progression following endocrine therapy.
Applications In Development:
Initial therapy in combination with letrozole for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer.
Acquisition Date:
In January 2016, Royalty Pharma commits to fund a Pfizer program testing Ibrance in adjuvant breast cancer
Royalty Seller:



ibrance color logo
"In the two years since its initial approval, IBRANCE has been prescribed to more than 50,000 patients by more than 9,800 physicians in the U.S.,” said Liz Barrett, global president and general manager, Pfizer Oncology. “This important update to the IBRANCE label underscores the strength of the data we continue to generate for IBRANCE. We are proud of the impact this innovative medicine continues to have on patients’ lives."


Latest News

  • Pfizer metastatic breast cancer medicine wins "Best Pharmaceutical Product" award
    28 October 2016
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.